Investigating how to regulate a gene linked to Alzheimer's disease using new delivery methods.
Official title: Therapeutic effects of APOE regulation via LNP-RNA formulations in Alzheimer's disease
Funded at Icahn School of Medicine at Mount Sinai · NIH-11105008 · Data updated 2026-11-12
This study is looking at how a specific gene related to Alzheimer's disease affects the risk of memory loss, and it's testing a new way to deliver treatments to the brain that could help improve care for people with this condition.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Icahn School of Medicine at Mount Sinai NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | June 1, 2025 |
| Project end | March 31, 2030 |
| Funding year | 2025 |
| Award (this year) | $835,417 |
| NIH project number | 1R01AG092823-01 |
| Project ID | NIH-11105008 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals diagnosed with Alzheimer's disease, particularly those with genetic risk factors related to the ApoE gene.
✕Less likely to help
Patients without a diagnosis of Alzheimer's disease or those with other forms of dementia may not benefit from this research.
What this research studies
This research focuses on Alzheimer's disease (AD), a serious condition that leads to memory loss and cognitive decline. The team is exploring the role of the Apolipoprotein E (ApoE) gene, which has different variants that affect AD risk. They aim to develop lipid nanoparticles (LNPs) that can effectively deliver nucleic acid therapies to the brain, overcoming barriers that typically prevent such treatments from reaching their target. By modifying the expression of ApoE genes, the researchers hope to find new therapeutic strategies to combat Alzheimer's disease.
Why it matters
Potential benefit: If successful, this research could lead to innovative treatments that significantly improve outcomes for patients with Alzheimer's disease.
How similar studies have gone: Previous research has shown promise in using nucleic acid-based therapies for neurodegenerative diseases, but this specific approach targeting ApoE regulation is relatively novel.
Where this research is happening
-
Icahn School of Medicine at Mount Sinai
New York, United States Active
Researchers
- Principal investigator: Dong, Yizhou — Icahn School of Medicine at Mount Sinai
- Study coordinator: Dong, Yizhou
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.